Successful non-myeloablative allogeneic HLA-identical stem cell transplantation for CD4/CD56 positive acute leukemia [3]

Transplantation

Volumn 84, Issue 8, 2007, Pages 1066-1067

  Amor, Ramzi Ben ^a   Hicheri, Yosr ^a   Pautas, Cécile ^a   Jouault, Hélène ^a   Kuentz, Mathieu ^a   Cordonnier, Catherine ^a   Maury, Sebastien ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CD4 ANTIGEN; CD56 ANTIGEN; CELL ADHESION MOLECULE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; FLUDARABINE; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; VINCRISTINE;

ACUTE LEUKEMIA; ADULT; BONE MARROW BIOPSY; BRAIN RADIATION; BRAIN TUMOR; CANCER RELAPSE; CASE REPORT; CELL PROLIFERATION; CHROMOSOME ANALYSIS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; GENETIC TRANSCRIPTION; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; LETTER; NATURAL KILLER CELL; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; T LYMPHOCYTE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ACUTE DISEASE; ANTIGENS, CD4; ANTIGENS, CD56; FEMALE; HLA ANTIGENS; HUMANS; LEUKEMIA; MIDDLE AGED; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 37349078639     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000286098.28481.7d     Document Type: Letter

References (10)

1. Susuki BR, Yamamoto K, Seto M, et al. CD7+ and CD56+ myeloid/Natural Killer cell precursor acute leukemia: A distinct hematolymphoid disease entity. Blood 1997; 90: 2417.
2. Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F. Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica 2002; 87: 250.
3. Chang H, Brandwein J, Hi QL, Chun K, Patterson B, Brein B. Extramedullary infiltrates of acute myeloid leukemia are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res 2004; 28: 1007.
4. Susuki R, Murata M, Kami M, et al. Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukaemia MO. Int J Hematol 2003; 77: 482.
5. Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4+CD56+ malignancies. Blood 2002; 99: 1556.
6. Slater DN. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: A practical marriage of two giants. Br J Dermatol 2005; 153: 874.
7. Leung R, Chow EE, Au WY, et al. CD4+/CD56+ hematologic malignancy with rearranged MLL gene. Human Pathol 2006; 37: 247.
8. Rossi JG, Felice MS, Bernasconi AR, et al. Acute leukemia of dendritic cell lineage in chilhood: Incidence, biological characteristics and outcome. Leuk Lymphoma 2006; 47: 715.
9. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low - dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444.
10. Reimer P, Rudiger T, Kraemer D, et al. What is CD4+ CD56+ malignancy and how should it be treated? BMT 2003; 32: 637.